Source: EURLEX
Language: en
Format: md

|  |  |  |  |
| --- | --- | --- | --- |
| 31.7.2017 | EN | Official Journal of the European Union | C 249/41 |

---

Action brought on 6 June 2017 — Genomic Health v EUIPO (ONCOTYPE DX GENOMIC PROSTATE SCORE)

(Case T-354/17)

(2017/C 249/55)

Language of the case: English

Parties

Applicant: Genomic Health, Inc. (Redwood City, California, United States) (represented by: A. Reid, Solicitor)

Defendant: European Union Intellectual Property Office (EUIPO)

Details of the proceedings before EUIPO

Trade mark at issue: EU word mark ‘ONCOTYPE DX GENOMIC PROSTATE SCORE’ — Application for registration No 15 214 257

Contested decision: Decision of the Fifth Board of Appeal of EUIPO of 14 February 2017 in Case R 1682/2016-5

Form of order sought

The applicant claims that the Court should:

|  |  |
| --- | --- |
| — | annul the contested decision; |

|  |  |
| --- | --- |
| — | order EUIPO to pay the Applicant’s costs of and occasioned by this appeal. |

Pleas in law

The Applicant submits that the Contested Decision is incorrect and constitutes an:

|  |  |
| --- | --- |
| — | Infringement of the general principles of equal treatment, good administration and legal certainty; |

|  |  |
| --- | --- |
| — | Infringement of Article 7(1)(b) in conjunction with Article 7(2) of Regulation No 207/2009; |

|  |  |
| --- | --- |
| — | Infringement of Article 7(1)(c) in conjunction with Article 7(2) of Regulation No. 207/2009. |

---

[Top](#document1)